Intravenous immune globulin prevents venular vaso-occlusion in sickle cell mice by inhibiting leukocyte adhesion and the interactions between sickle erythrocytes and adherent leukocytes

Blood

Volumn 103, Issue 6, 2004, Pages 2397-2400

  Turhan, Aslihan ^b   Jenab, Pegah ^b   Bruhns, Pierre ^b   Ravetch, Jeffrey V ^b   Coller, Barry S ^b   Frenette, Paul S ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN; IMMUNOGLOBULIN G; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD FLOW; CELL INTERACTION; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; ERYTHROCYTE; HUMAN; LEUKOCYTE ADHERENCE; MICROSCOPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SICKLE CELL ANEMIA; TREATMENT OUTCOME; VEIN OCCLUSION;

EID: 1542343932     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2003-07-2209     Document Type: Article

References (26)

1. Embury SH, Vichinsky E. Sickle cell disease. In: Hoffman R, Benz EJ, Shattiil SJ, et al, eds. Hematology: Basic Principles and Practice. Philadelphia, PA: Churchill Livingstone; 2000:510-554.
2. Duits AJ, Pieters RC, Saleh AW, et al. Enhanced levels of soluble VCAM-1 in sickle cell patients and their specific increment during vasoocclusive crisis. Clin Immunol Immunopathol. 1996;81:96-98.
3. Solovey A, Lin Y, Browne P, et al. Circulating activated endothelial cells in sickle cell anemia. N Engl J Med. 1997;337:1584-1590.
4. Kaul DK, Hebbel RP. Hypoxia/reoxygenation causes inflammatory response in transgenic sickle mice but not in normal mice. J Clin Invest. 2000;106:411-420.
5. Belcher JD, Bryant CJ, Nguyen J, et al. Transgenic sickle mice have vascular inflammation. Blood. 2003;101:3953-3959.
6. Platt OS. Sickle cell anemia as an inflammatory disease. J Clin Invest. 2000;106:337-338.
7. Hofstra TC, Kalra VK, Meiselman HJ, Coates TD. Sickle erythrocytes adhere to polymorphonuclear neutrophils and activate the neutrophil respiratory burst. Blood. 1996;87:4440-4447.
8. Turhan A, Weiss LA, Mohandas N, Coller BS, Frenette PS. Primary role for adherent leukocytes in sickle cell vascular occlusion: a new paradigm. Proc Natl Acad Sci U S A. 2002;99:3047-3051.
9. Frenette PS. Sickle cell vaso-occlusion: multistep and multicellular paradigm. Curr Opin Hematol. 2002;9:101-106.
10. Paszty C, Brion CM, Manci E, et al. Transgenic knockout mice with exclusively human sickle hemoglobin and sickle cell disease. Science. 1997;278:876-878.
11. Alter BP, Goff SC, Efremov GD, Gravely ME, Huisman TH. Globin chain electrophoresis: a new approach to the determination of the G gamma/A gamma ratio in fetal haemoglobin and to studies of globin synthesis. Br J Haematol. 1980;44:527-534.
12. Bruhns P, Samuelsson A, Pollard JW, Ravetch JV. Colony-stimulating factor-1 -dependent macrophages are responsible for IVIG protection in antibody-induced autoimmune disease. Immunity. 2003;18:573-581.
13. Frenette PS. Sickle cell vaso-occlusion: heterotypic, multicellular, aggregations driven by leukocyte adhesion. Microcirculation. In press.
14. Petz LD, Yam P, Wilkinson L, et al. Increased IgG molecules bound to the surface of red blood cells of patients with sickle cell anemia. Blood. 1984;64:301-304.
15. Hebbel RP, Miller WJ. Phagocytosis of sickle erythrocytes: immunologic and oxidative determinants of hemolytic anemia. Blood. 1984;64:733-741.
16. Green GA, Rehn MM, Kalra VK. Cell-bound autologous immunoglobulin in erythrocyte subpopulations from patients with sickle cell disease. Blood. 1985;65:1127-1133.
17. Green GA, Kalra VK. Sickling-induced binding of immunoglobulin to sickle erythrocytes. Blood. 1988;71:636-639.
18. Samuelsson A, Towers TL, Ravetch JV. Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science. 2001;291:484-486.
19. 2-mediated neutralization of C3a and C5a anaphylatoxins: a novel effector function of immunoglobulins. Nat Med. 2003;9:431-438.
20. Cullis JO, Win N, Dudley JM, Kaye T. Post-transfusion hyperhaemolysis in a patient with sickle cell disease: use of steroids and intravenous immunoglobulin to prevent further red cell destruction. Vox Sang. 1995;69:355-357.
21. Win N, Doughty H, Telfer P, Wild BJ, Pearson TC. Hyperhemolytic transfusion reaction in sickle cell disease. Transfusion. 2001;41:323-328.
22. Gangarossa S, Lucini NR. High-dose intravenous immunoglobulin therapy, blood rheology, and sickle cell anemia. Pediatr Hematol Oncol. 1993; 10:377-378.
23. Cantu TG, Hoehn-Saric EW, Burgess KM, Racusen L, Scheel PJ. Acute renal failure associated with immunoglobulin therapy. Am J Kidney Dis. 1995;25:228-234.
24. Gupta N, Ahmed I, Nissel-Horowitz S, Patel D, Mehrotra B. Intravenous gammglobulin-associated acute renal failure. Am J Hematol. 2001;66:151-152.
25. Go RS, Call TG. Deep venous thrombosis of the arm after intravenous immunoglobulin infusion: case report and literature review of intravenous immunoglobulin-related thrombotic complications. Mayo Clin Proc. 2000;75: 83-85.
26. Caress JB, Cartwright MS, Donofrio PD, Peacock JE Jr. The clinical features of 16 cases of stroke associated with administration of IVIg. Neurology. 2003;60:1822-1824.